Global Vaccine Adjuvants Market by Application

According to the new market research report “Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021", published by MarketsandMarkets™, report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the vaccine adjuvants market along with the estimates and forecasts of the revenue and market share analysis.

The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016 at a CAGR of 10.5% from 2016 to 2021. The major factors driving the growth of this market are high prevalence of infectious and zoonotic diseases, increasing focus on immunization programs by various government bodies, and growing focus on improved and long-lasting immunization against existing and emerging diseases.
Based on applications, the global vaccine adjuvants market is segmented into research and commercial applications. Research applications are expected to account for the largest share of the market during the forecast period. Growth in this segment is driven by factors such as increasing need for better immunization for the increasing geriatric population and increasing government funding in research to meet the unmet needs for safe and effective vaccine adjuvants.


On the basis of application categories, the vaccine adjuvants market is segmented into human and veterinary adjuvants. Adjuvants for humans are expected to account for the largest share of the global vaccine adjuvants market in 2016 and are expected to grow at a higher CAGR in the application category segment.

The key players in the vaccine adjuvants market include Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).
Location: Dundee Rd, Illinois, USA

Comments

Post a Comment

Popular posts from this blog

Key Players in the Pyrogen Testing Market Focus on Partnerships, Agreements, & Collaborations, Acquisitions, New Product launches, and Expansions

Image
The report  " Pyrogen Testing Market  by Product (Instruments, Services, Kits and Reagents), Application (Pharmaceutical & Biotechnology, Medical Devices, Other), & by Test (In Vitro, LAL, Gel Clot, Turbidimetric, Chromogenic, Rabbit) - Global Forecasts to 2021 " ,  report provides a detailed overview of the major drivers, restraints, opportunities, current market trends, and strategies impacting the global pyrogen testing market along with the estimates and forecasts of the revenue and market share analysis. Speak to Analyst @  https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=255266155 The global pyrogen testing market is valued at $462.38 million in 2014 and is expected to grow at a CAGR of 12.23%, to reach $823.14 million by 2019. Pyrogen testing is used to determine the bacterial toxins in products intended for medical or veterinary use. Rapidly growing pharmaceutical and biotechnology industries are a major growth driver for this market. Further
Read more

Non Invasive Prenatal Testing Market| Market Trends by Instruments, Consumables, Method, Application and End User

The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period. The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016, at a CAGR of 16.4% from 2016 to 2021. The instruments segment is divided into ultrasound device, NGS systems, PCR instruments, microarrays, and other instruments. In 2016, the consumables segment accounted for the largest share of the market. The high growth in this segment is attributed to the repeated requirements of consumables as compared to instruments in NIPT. Based on application
Read more

Global Glycomics Market Players Pursue the Strategies of Product Launches, Agreements, Expansions, Acquisitions, and Collaborations

Image
The major players in this market include Agilent Technologies (U.S.), Bruker Corp. (U.S.), Danaher Corp. (U.S.), New England Biolabs (U.S.), Prozyme Inc. (U.S.), Shimadzu Corp. (Japan), Sigma-Aldrich Corp. (U.S.), Takara Bio (Japan), Thermo Fisher Scientific (U.S.), and Waters Corp. (U.S.). The glycomics market is dominated by a few major players, with the top five players accounting for a majority of the market share. The top four players for glycomics enzymes, kits, and reagents have a combined market share of about 75.2% and for glycomics instruments have a combined market share of about 76.0%. The global glycomics market is highly evolved, with multiple different product segments. An analysis of market developments between 2011 and 2014 revealed that new product launches was the most important growth strategy employed by market leaders in this period. This strategy was adopted by most players in this market, except New England Biolabs (U.S.) and Takara Bio, Inc. (Japan).
Read more